Life sciences organizations are under increasing pressure to balance speed, control, and scalability in their AI strategies. Many initiatives, however, continue to stall at the pilot stage due to fragmented systems and governance challenges.
In this session, we explored how commercial teams evaluate the Build, Buy, and Blend decision when scaling AI. We walked through practical decision frameworks, key trade‑offs across each approach, and how organizations combine foundational AI platforms with differentiated intelligence layers to drive real‑world impact. The discussion highlighted how the right strategy can accelerate speed to insight, improve scalability, and deliver stronger commercial outcomes.
